Zobrazeno 1 - 10
of 2 641
pro vyhledávání: '"Fibroblast growth factor receptor 3"'
Publikováno v:
Jichu yixue yu linchuang, Vol 44, Iss 11, Pp 1530-1537 (2024)
Objective To investigate the effect of fibroblast growth factor receptor 3 (FGFR3) on articular cartilage superficial zone cells (SPZCs). Methods C57 mice were randomly divided into two groups: a sham operated group (sham group) and a group of surgic
Externí odkaz:
https://doaj.org/article/52b13288f66c43caa9880837c992ef7c
Autor:
Dereje E. Bogale
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Bladder cancer is one of the most frequently occurring cancers worldwide. At diagnosis, 75% of urothelial bladder cancer cases have non-muscle invasive bladder cancer while 25% have muscle invasive or metastatic disease. Aberrantly activated
Externí odkaz:
https://doaj.org/article/0f39e133ecfe4951bd109a6ff367534c
Publikováno v:
Nigerian Journal of Paediatrics, Vol 47, Iss 3, Pp 277-279 (2024)
Thanatophoric dysplasia is a lethal form of skeletal dysplasia seen in neonates. The word ‘thanatophoric’ is derived from the Greek word thanatophorus meaning death bringing. Thanatophoric dysplasia results from mutations within the Fibroblast Gr
Externí odkaz:
https://doaj.org/article/0900439d31244af7a8f4d8c633319805
Publikováno v:
Endocrine Journal, Vol 71, Iss 7, Pp 643-650 (2024)
Achondroplasia (ACH) is a representative skeletal disorder characterized by rhizomelic shortened limbs and short stature. ACH is classified as belonging to the fibroblast growth factor receptor 3 (FGFR3) group. The downstream signal transduction of F
Externí odkaz:
https://doaj.org/article/f10d452caa274538b4c80158bd60eb0d
Autor:
Kengo Hiranuma, Yuka Asami, Mayumi Kobayashi Kato, Naoya Murakami, Yoko Shimada, Maiko Matsuda, Shu Yazaki, Erisa Fujii, Kazuki Sudo, Ikumi Kuno, Masaaki Komatsu, Ryuji Hamamoto, Hideki Makinoshima, Koji Matsumoto, Mitsuya Ishikawa, Takashi Kohno, Yasuhisa Terao, Atsuo Itakura, Hiroshi Yoshida, Kouya Shiraishi, Tomoyasu Kato
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17835-17848 (2023)
Abstract Background Although cervical cancer is often characterized as preventable, its incidence continues to increase in low‐ and middle‐income countries, underscoring the need to develop novel therapeutics for this disease.This study assessed
Externí odkaz:
https://doaj.org/article/16a7ff7c704942b4a949ca70b9e89c21
Autor:
Mohamad Maghnie, Oliver Semler, Encarna Guillen-Navarro, Angelo Selicorni, Karen E. Heath, Gabriele Haeusler, Lars Hagenäs, Andrea Merker, Antonio Leiva-Gea, Vanesa López González, Adalbert Raimann, Mirko Rehberg, Fernando Santos-Simarro, Diana-Alexandra Ertl, Pernille Axél Gregersen, Roberta Onesimo, Erik Landfeldt, James Jarrett, Jennifer Quinn, Richard Rowell, Jeanne Pimenta, Shelda Cohen, Thomas Butt, Renée Shediac, Swati Mukherjee, Klaus Mohnike
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-19 (2023)
Abstract Background Achondroplasia, caused by a pathogenic variant in the fibroblast growth factor receptor 3 gene, is the most common skeletal dysplasia. The Lifetime Impact of Achondroplasia Study in Europe (LIAISE; NCT03449368) aimed to quantify t
Externí odkaz:
https://doaj.org/article/396b4128425f4efaa0a0c79776e03d51
Publikováno v:
BMC Pediatrics, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Hypochondroplasia (HCH) is a common nonlethal skeletal dysplasia caused by pathogenic variations in the fibroblast growth factor receptor 3 (FGFR3) gene, and HCH has similar clinical manifestations with achondroplasia (ACH), which
Externí odkaz:
https://doaj.org/article/b55f5b774dab4645a63430aa7e285dee
Publikováno v:
Неонатологія, хірургія та перинатальна медицина, Vol 13, Iss 3(49) (2023)
Thanatophoric dysplasia, TD (OMIM: 187600, 87601) belongs to the group of FGFR3 chondrodysplasias and is divided into types I and II. The incidence of TD is approximately 1:20,000-50,000 newborns. TD is usually caused by pathogenic variants in the FG
Externí odkaz:
https://doaj.org/article/833b0100204c468ba1473abc7ad420e3
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundBladder cancer (BC) threatens the health of human beings worldwide because of its high recurrence rate and mortality. As an actionable biomarker, fibroblast growth factor receptor 3 (FGFR3) alterations have been revealed as a vital biomarke
Externí odkaz:
https://doaj.org/article/cac1bceed4b94ee9826f4f8f99fa4465
Autor:
Sidra Khalid, Bassam Mohammed Basulaiman, Jeffrey Emack, Christopher M. Booth, Ignacio Duran, Andrew G. Robinson, David Berman, Martin Smoragiewicz, Eitan Amir, Francisco E. Vera-Badillo
Publikováno v:
European Urology Open Science, Vol 21, Iss , Pp 61-68 (2020)
Background: Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. Objective: We aimed to study the association between FGFR3 mutations and survi
Externí odkaz:
https://doaj.org/article/97a165ed87b24c6d964a86fb6984384a